Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

• the present invention relates to novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity.
• This invention also relates to pharmaceutical compositions comprising such biphenyl compounds, processes and intermediates for preparing such biphenyl compounds and methods of using such biphenyl compounds to treat pulmonary disorders.
• Pulmonary or respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma
• COPD chronic obstructive pulmonary disease
• Muscarinic receptor antagonists are known to provide bronchoprotective effects and therefore, such compounds are useful for treating respiratory disorders, such as COPD and asthma.
• muscarinic receptor antagonists When used to treat such disorders, muscarinic receptor antagonists are typically administered by inhalation. However, even when administered by inhalation, a significant amount of the muscarinic receptor antagonist is often absorbed into the systemic circulation resulting in systemic side effects, such as dry mouth, mydriasis and cardiovascular side effects.
• inhaled muscarinic receptor antagonists have a relatively short duration of action requiring that they be administered several times per day. Such a multiple-daily dosing regime is not only inconvenient but also creates a significant risk of inadequate treatment due to patient non-compliance with the required frequent dosing schedule. Accordingly, a need exists for new muscarinic receptor antagonists. In particular, a need exists for new muscarinic receptor antagonists that having high potency and reduced systemic side effects when administered by inhalation. Additionally, a need exists for inhaled muscarinic receptor antagonists having a long duration of action thereby allowing for once-daily or even once-weekly dosing. Such compounds are expected to be particularly effective for treating pulmonary disorders, such as COPD and asthma, while reducing or eliminating side effects, such as dry-mouth and constipation.
• the present invention provides novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity.
• compounds of the invention are expected to possess high potency and reduced systemic side effects when administered by inhalation and to have a long duration of action. Accordingly, in one of its composition aspects, this invention provides a compound of formula I:
• each R 1 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR la , -C(O)OR l , -SR lc , -S(O)R ld , -S(O) 2 R le , -NR lf R lg , -NR ⁇ SCO ⁇ R 11 , and -NR lj C(O)R lk ; where each of R la , R lb , R lc , R ld , R le , R lf , R lg , R lh , R u , R lj , and R lk is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; b is 0 or an integer
• this invention is directed to a pharmaceutical composition
• a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• Such pharmaceutical compositions may optionally contain other therapeutic agents.
• this invention is directed to such a pharmaceutical composition wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent, such as a corticosteroid; a ⁇ 2 adrenergic receptor agonist; a phosphodiesterase-4 inhibitor; or a combination thereof.
• a steroidal anti-inflammatory agent such as a corticosteroid; a ⁇ 2 adrenergic receptor agonist; a phosphodiesterase-4 inhibitor; or a combination thereof.
• Compounds of this invention possess muscarinic receptor antagonist activity.
• this invention is directed to a method for treating a pulmonary disorder, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Additionally, in another of its method aspects, this invention is directed to a method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• This invention is also directed to a method of treating chronic obstructive pulmonary disease or asthma, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• this invention is directed to a method for antagonizing a muscarinic receptor in a mammal comprising administering to the mammal, a therapeutically effective amount of the compound of formula I. Since compounds of this invention possess muscarinic receptor antagonist activity, such compounds are also useful as research tools.
• this invention is directed to a method for using a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof as a research tool for studying a biological system or sample, or for discovering new chemical compounds having muscarinic receptor antagonist activity.
• This invention is also directed to processes and novel intermediates useful for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• this invention is directed to a process of preparing a compound of formula I, the process comprising: (a) reacting a compound of formula II with a compound of formula III; (b) coupling a compound of formula IV with a compound of formula N; (c) reacting a compound of formula NI with a compound of formula Nil; (d) reacting a compound of formula II with a compound of formula NIII in the presence of a reducing agent; or (e) reacting a compound of formula IX with a compound of formula Nil in the presence of a reducing agent; and then removing any protecting groups, if necessary, to provide a compound of formula I; wherein compounds of formula I-IX are as defined herein.
• the above process further comprises the step of forming a pharmaceutically acceptable salt of a compound of formula I.
• this invention is directed to the other processes described herein; and to the product prepared by any of the processes described herein.
• This invention is also directed to a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof, for use in therapy or as a medicament.
• this invention is directed to the use of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof, for the manufacture of a medicament; especially for the manufacture of a medicament for the treatment of a pulmonary disorder or for antagonizing a muscarinic receptor in a mammal.
• this invention is directed to novel biphenyl compounds of formula I or pharmaceutically acceptable salts or solvates or stereoisomers thereof. These compounds may contain one or more chiral centers and therefore, this invention is directed to racemic mixtures; pure stereoisomers (i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures and the like unless otherwise indicated.
• stereoisomer is shown or named herein, it will be understood by those skilled in the art that minor amounts of other stereoisomers may be present in the compositions of this invention unless otherwise indicated, provided that the desired utility of the composition as a whole is not eliminated by the presence of such other isomers.
• the compounds of formula I also contain several basic groups (e.g., amino groups) and therefore, the compounds of formula I can exist as the free base or in various salt forms. All such salt forms are included within the scope of this invention. Furthermore, solvates of compounds of formula I or salts thereof are included within the scope of this invention. Additionally, where applicable, all cis-trans or E/Z isomers (geometric isomers), tautomeric forms and topoisomeric forms of the compounds of formula I are included within the scope of this invention unless otherwise specified.
• the compounds of formula I may also include isotopically- labeled compounds, i.e., where one or more atoms have been enriched with atoms having an atomic mass different from the atomic mass predominately found in nature.
• isotopes that may be incorporated into the compounds of Formula (I) include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O and 17 O.
• the nomenclature used herein to name the compounds of this invention is illustrated in the Examples herein. This nomenclature has been derived using the commercially-available AutoNom software (MDL, San Leandro, California).
• Each R 1 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR la , -C(O)OR lb , -SR lc , -S(O)R ld , - S(O) 2 R le , -NR lf R lg , -NR lh S(O) 2 R li , and -NR lj C(O)R lk , examples of which include methyl, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, dimethylamino and the like.
• each R 2 may be at the 3, 4, 5 or 6-position on the phenylene ring to which it is attached (where the carbon atom on the phenylene ring attached to the nitrogen atom is position 1).
• Each R 2 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR 2a , -C(O)OR 2 , -SR 2c , -S(O)R 2d , -
• these groups are independently hydrogen or (l-3C)alkyl. In another embodiment, these groups are independently hydrogen, methyl or ethyl.
• each alkyl and alkoxy group in R 1 , R la"lk , R 2 , and R 2 "2k is optionally substituted with 1 to 5 fluoro substituents.
• W is O. In another embodiment, W is NW a . Generally, it has been found that compounds in which W represents O exhibit particularly high affinity for muscarinic receptors. Accordingly, in a particular embodiment of this invention, W represents O.
• W a is hydrogen or (l-4C)alkyl, examples of which include hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl.
• W a is hydrogen or (l-3C)alkyl.
• W a is hydrogen, methyl or ethyl, particularly hydrogen or methyl.
• W a is The value for c is 0, 1, 2, 3, or 4; particularly 0, 1, or 2; and more particularly 0 or 1. In one particular embodiment, c is 0.
• Each R 3 independently represents (l-4C)alkyl or two R 3 groups that are joined to form (l-3C)alkylene, (2-3C)alkenylene or oxiran-2,3-diyl.
• each R 3 is independently (l-4C)alkyl, such as methyl, ethyl, n-propyl, isopropyl, n -butyl, sec-butyl, isobutyl and tert-butyl.
• each alkyl group in R 3 is optionally substituted with 1 to 5 fluoro substituents.
• each R 3 is independently (l-3C)alkyl, and in another embodiment, each R 3 is independently methyl or ethyl. In one embodiment, each R is at the 3, 4 or 5-position on the piperidine ring
• R is at the 4-pos ⁇ tion on the piperidine ring.
• R is at the 1- position of the piperidine ring, i.e., on the nitrogen atom of the piperidine ring thus forming a quaternary a ine salt.
• two R 3 groups are joined to form a (l-3C)alkylene or
• (2-3C)alkenylene group For example, two R 3 groups at the 2 and 6-positions on the piperidine ring can be joined to form an ethylene bridge (i.e., the piperidine ring and the R 3 groups form an 8-azabicyclo[3.2.1]octane ring); or two R 3 groups at the 1 and 4-positions on the piperidine ring can be joined to form an ethylene bridge (i.e., the piperidine ring and the R 3 groups form an l-azabicyclo[2.2.2]octane ring).
• other R 3 groups as defined herein may also be present.
• two R 3 groups are joined to form a oxiran-2,3-diyl group.
• R 4 represents hydrogen, (l-4C)alkyl, or (3-4C)cycloalkyl.
• (l-4C)alkyl include methyl, ethyl, n-propyl, isopropyl, «-butyl, sec-butyl, isobutyl and tert-butyl.
• Examples of (3-4C)cycloalkyl groups include cyclopropyl and cyclobutyl.
• R 4 represents hydrogen or (l-3C)alkyl.
• R 4 is hydrogen or methyl.
• R 4 is hydrogen.
• the value for r is 2, 3, or 4.
• r is 3.
• the value for n is 0, 1, 2, or 3.
• Particular values for n are 1 or 2.
• n is 2.
• the value for d is 0, 1, 2, 3, or 4.
• Particular values for d are 0, 1 or 2.
• d is 0.
• Each R 5 independently represents fluoro or (l-4C)alkyl, examples of which include methyl, ethyl, n-propyl, isopropyl, «-butyl, sec-butyl, isobutyl and tert-butyl.
• each alkyl and alkoxy group in R 5 is optionally substituted with 1 to 5 fluoro substituents.
• each R 5 independently represents fluoro or (l-sC)alkyl, and in another embodiment, each R 5 is independently selected from fluoro, methyl, ethyl or trifluoromethyl.
• the value for p is 0 or 1. In one particular embodiment, p is 0.
• R 6 and R 7 are both hydrogen, ethyl or propyl.
• R is methyl and R is ethyl.
• each alkyl and alkoxy group in R 6 and R 7 is optionally substituted with 1 to 5 fluoro substituents.
• ⁇ 7 As noted in formula I, the -CONR R group can be located at any carbon atom on the ring. For example, when n is 2, the group can be located at the ortho, meta £ 7 or para position. In one embodiment, the -CONR R group is located at the meta or para position; and in a particular embodiment, the group is located at the para position.
• one group of compounds of interest are compounds of formula I wherein a, b, c, d, m and p are 0; r is 3; and n is 2.
• Another particular group of compounds of interest are compounds of formula I, where a, b, c, d, m, and p are 0; n is 2; W is O; and R 7 is hydrogen.
• R 4 , R 6 and r are as defined herein; or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• a particular group of compounds of formula I are those disclosed in U. S .
• Another particular group of compounds of interest are compounds of formula F where a, b, c, d, and m are 0; n is 1; and W is O.
• Particular compounds of interest include: biphenyl-2-ylcarbamic acid 1 -(2- ⁇ [6-(4-carbamoylpiperidin- 1 -yl)hexanoyl] methylamino ⁇ ethyl)piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l- ⁇ 2-[6-((R)-3-diethylcarbamoylpiperidin-l-yl) hexanoylamino] ethyl ⁇ piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-(2- ⁇ [6-((R)-3-dipropylcarbamoylpiperidin-l-yl) hexanoyljmethylamino ⁇ eth
• alkyl means a monovalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkyl groups typically contain from 1 to 10 carbon atoms. Representative alkyl groups include, by way of example, methyl, ethyl, «-propyl, isopropyl, ra-butyl, sec-butyl, isobutyl, tert-butyl, 7j-pentyl, n-hexyl, «-heptyl, n- octyl, «-nonyl, n-decyl and the like.
• alkylene means a divalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkylene groups typically contain from 1 to 10 carbon atoms. Representative alkylene groups include, by way of example, methylene, ethane- 1,2-diyl ("ethylene”), propane- 1,2-diyl, propane-l,3-diyl, butane-1,4- diyl, pentane-l,5-diyl and the like.
• alkoxy means a monovalent group of the formula (alkyl)-O- where alkyl is as defined herein.
• alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, r ⁇ -butoxy, sec-butoxy, isobutoxy, tert-butoxy and the like.
• alkenyl means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon double bonds. Unless otherwise defined, such alkenyl groups typically contain from 2 to 10 carbon atoms.
• Representative alkenyl groups include, by way of example, ethenyl, n- propenyl, isopropenyl, /z-but-2-enyl, ⁇ z-hex-3-enyl and the like.
• alkenylene means a divalent alkenyl group.
• alkynyl means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon- carbon triple bonds. Unless otherwise defined, such alkynyl groups typically contain from 2 to 10 carbon atoms. Representative alkynyl groups include, byway of example, ethynyl, n-propynyl, «-but-2-ynyl, w-hex-3-ynyl and the like.
• alkynylene means a divalent alkynyl group.
• aryl means a monovalent aromatic hydrocarbon having a single ring (i.e., phenyl) or fused rings (i.e., naphthalene). Unless otherwise defined, such aryl groups typically contain from 6 to 10 carbon ring atoms. Representative aryl groups include, by way of example, phenyl and naphthalene- 1-yl, naphthalene-2-yl, and the like.
• arylene means a divalent aryl group.
• azacycloalkyl means a monovalent heterocyclic ring containing one nitrogen atom, i.e., a cycloalkyl group in which one carbon atom has been replaced with a nitrogen atom.
• azacycloalkyl groups typically contain from 2 to 9 carbon atoms.
• Representative examples of an azacycloalkyl group are pyrrolidinyl and piperidinyl groups.
• azacycloalkylene means a divalent azacycloakyl group.
• Representative examples of an azacycloalkylene group are pyrrolidinylene and piperidinylene groups.
• cycloalkyl means a monovalent saturated carbocyclic hydrocarbon group. Unless otherwise defined, such cycloalkyl groups typically contain from 3 to 10 carbon atoms.
• cycloalkyl groups include, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
• cycloalkylene means a divalent cycloalkyl group.
• halo means fluoro, chloro, bromo and iodo.
• heteroaryl means a monovalent aromatic group having a single ring or two fused rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur. Unless otherwise defined, such heteroaryl groups typically contain from 5 to 10 total ring atoms.
• heteroaryl groups include, by way of example, monovalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, triazole, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, indole, benzofuran, benzothiophene, benzimidazole, benzthiazole, quinoline, isoquinoline, quinazoline, quinoxaline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
• heteroarylene means a divalent heteroaryl group.
• heterocyclyl or “heterocyclic” means a monovalent saturated or unsaturated (non-aromatic) group having a single ring or multiple condensed rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur. Unless otherwise defined, such heterocyclic groups typically contain from 2 to 9 total ring carbon atoms.
• Representative heterocyclic groups include, by way of example, monovalent species of pyrrolidine, imidazolidine, pyrazolidine, piperidine, 1,4-dioxane, morpholine, thiomorpholine, piperazine, 3-pyrroline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
• heterocyclene means a divalent heterocyclyl or heterocyclic group.
• (l-4C)alkyl means an alkyl group having from 1 to 4 carbon atoms.
• pharmaceutically acceptable salt means a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
• Salts derived from pharmaceutically acceptable inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Particularly preferred are ammonium, calcium, magnesium, potassium and sodium salts.
• Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, NN-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethyle ⁇ ediamine, ⁇ -ethylmorpholine, ⁇ - ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine,* morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
• arginine betaine
• caffeine choline
• Salts derived from pharmaceutically acceptable acids include acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, edisylic, fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, naphthalene- 1,5-disulfonic, naphthalene-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, xinafoic and the like.
• citric, hydrobromic, hydrochloric, isethionic, maleic, naphthalene- 1, 5 -disulfonic, phosphoric, sulfuric and tartaric acids are particularly preferred.
• salt thereof means a compound formed when the hydrogen of an acid is replaced by a cation, such as a metal cation or an organic cation and the like.
• the salt is a pharmaceutically acceptable salt, although this is not required for salts of intermediate compounds that are not intended for administration to a patient.
• solvate means a complex or aggregate formed by one or more molecules of a solute, i.e. a compound of formula I or a pharmaceutically acceptable salt thereof, and one or more molecules of a solvent.
• Such solvates are typically crystalline solids having a substantially fixed molar ratio of solute and solvent.
• Representative solvents include, by way of example, water, methanol, ethanol, isopropanol, acetic acid and the like. When the solvent is water, the solvate formed is a hydrate.
• the term "or a pharmaceutically acceptable salt or solvate or stereoisomer thereof is intended to include all permutations of salts, solvates and stereoisomers, such as a solvate of a pharmaceutically acceptable salt of a stereoisomer of a compound of formula I.
• therapeutically effective amount means an amount sufficient to effect treatment when administered to a patient in need of treatment.
• treating means the treating or treatment of a disease or medical condition (such as COPD) in a patient, such as a mammal (particularly a human) that includes: (a) preventing the disease or medical condition from occurring, i.e., prophylactic treatment of a patient; (b) ameliorating the disease or medical condition, i.e., eliminating or causing regression of the disease or medical condition in a patient; (c) suppressing the disease or medical condition, i.e., slowing or arresting the development of the disease or medical condition in a patient; or (d) alleviating the symptoms of the disease or medical condition in a patient.
• a disease or medical condition such as COPD
• a mammal particularly a human
• leaving group means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction.
• representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
• protected derivatives thereof means a derivative of the specified compound in which one or more functional groups of the compound are protected from undesired reactions with a protecting or blocking group.
• Functional groups which may be protected include, by way of example, carboxylic acid groups, amino groups, hydroxyl groups, thiol groups, carbonyl groups and the like.
• Representative protecting groups for carboxylic acids include esters (such as a/>-methoxybenzyl ester), amides and hydrazides; for amino groups, carbamates (such as tert-butoxycarbonyl) and amides; for hydroxyl groups, ethers and esters; for thiol groups, thioethers and thioesters; for carbonyl groups, acetals and ketals; and the like.
• Such protecting groups are well-known to those skilled in the art and are described, for example, in T. W. Greene and G. M.
• amino-protecting group means a protecting group suitable for preventing undesired reactions at an amino group.
• Representative amino-protecting groups include, but are not limited to, tcrt-butoxycarbonyl (BOC), trityl (Tr), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), formyl, trimethylsilyl (TMS), tert- butyldimethylsilyl (TBS), and the like.
• carboxy-protecting group means a protecting group suitable for preventing undesired reactions at a carboxy group.
• Representative carboxy-protecting groups include, but are not limited to, esters, such as methyl, ethyl, tert-butyl, benzyl (Bn), j methoxybenzyl (PMB), 9-fluroenylmethyl (Fm), trimethylsilyl (TMS), tert- butyldimethylsilyl (TBS), diphenylmethyl (benzhydryl, DPM) and the like.
• hydroxyl-protecting group means a protecting group suitable for preventing undesirable reactions at a hydroxyl group.
• hydroxyl-protecting groups include, but are not limited to, silyl groups including tri(l-6C)alkylsilyl groups, such as trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS) and the like; esters (acyl groups) including (l-6C)alkanoyl groups, such as formyl, acetyl and the like; arylmethyl groups, such as benzyl (Bn), ⁇ -methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), diphenylmethyl (benzhydryl, DPM) and the like.
• silyl groups including tri(l-6C)alkylsilyl groups such as trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS) and the like
• biphenyl compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures or by using other information readily available to those of ordinary skill in the art. Although a particular embodiment of the present invention may be shown or described herein, those skilled in the art will recognize that all embodiments or aspects of the present invention can be prepared using the methods described herein or by using other methods, reagents and starting materials known to those skilled in the art.
• the compounds of formula I can be prepared by a process comprising: (a) reacting a compound of formula II:
• a salt of one of the starting materials is used in the processes described above, such as an acid addition salt, the salt is typically neutralized before or during the reaction process. This neutralization reaction is typically accomplished by contacting the salt with one molar equivalent of a base for each molar equivalent of acid addition salt.
• the reaction between the compounds of formula II and III, the leaving represented by Z can be, for example, halo, such as chloro, bromo or iodo, or a sulfonic ester group, such as mesylate or tosylate.
• the reaction is conveniently performed in the presence of a base, for example, a tertiary amine such as diisopropylethylamine.
• Convenient solvents include nitriles, such as acetonitrile.
• the reaction is conveniently conducted at a temperature in the range of from 0°C to 100°C.
• Compounds of formula II are generally known in the art, or can be prepared by deprotecting a compound of formula X:
• P represents an amino-protecting group, such as a benzyl group.
• Benzyl groups are conveniently removed by reduction, using a hydrogen or ammonium formate and a Group Vm metal catalyst, such as palladium.
• W represents NW a
• the hydrogenation is conveniently performed using Pearlman's catalyst (Pd(OH) 2 ).
• Compounds of formula X can be prepared by reacting an isocyanate compound of formula XI:
• XII with a compound of formula XII: XII
• Compounds of formula III can be prepared starting from a corresponding compound in which Z 1 represents a hydroxyl group, for example, by reaction of a halogenating agent, such as thionyl chloride, to afford a compound of formula III in which Z 1 represents halo, such as chloro.
• Compounds in which Z 1 represents a hydroxyl group may be prepared, for example, by reacting a compound of formula V with an appropriate amino-substituted alcohol, such as 2-aminoethanol or 3-aminopropan-l-ol.
• a compound of formula IN is reacted with a compound of formula N or reactive derivative thereof.
• reactive derivative of compound N, it is meant that the carboxylic acid is activated, for example, by forming an anhydride or carboxylic acid halide, such as a carboxylic acid chloride.
• carboxylic acid can be activated using conventional carboxylic acid/amine coupling reagents, such carbodiimides, O-(7-azabenzotriazol-l-yl-NNN',N' tetramethyluronium hexafluorophosphate (HATU) and the like.
• This reaction is conveniently performed under conventional amide bond- forming conditions. The process is conveniently conducted at a temperature in the range of from -10°C to l00°C.
• Compounds of formula IN can be prepared by reacting a compound of formula II with a compound of formula XIII: OHC(CH 2 ) m CH 2 NR 4 P 2 XIII wherein P 2 represents hydrogen or an amino-protecting group, such as benzyl, in the presence of a reducing agent, such as sodium triacetoxyborohydride, followed if necessary by removing the amino-protecting group P 2 by, for example, hydrogenation in the presence of palladium.
• a reducing agent such as sodium triacetoxyborohydride
• Compounds of formula V can be prepared by reacting a compound of formula Nil with a compound of formula XIN: XIN wherein P represents hydrogen or a carboxyl-protecting group, such as methyl or ethyl, and Z represents a leaving group, followed if necessary by removing the carboxyl protecting group P 3 .
• P represents hydrogen or a carboxyl-protecting group, such as methyl or ethyl
• Z represents a leaving group
• the leaving group represented by Z 2 can be, for example, halo, such as chloro, bromo or iodo, or a sulfonic ester group, such as mesylate or tosylate.
• This reaction is conveniently performed in the presence of a base, for example, a tertiary amine such as diisopropylethylamine.
• a base for example, a tertiary amine such as diisopropylethylamine.
• Convenient solvents include nitriles, such as acetonitrile. The reaction is conveniently conducted at a temperature in the range of from
• the compounds of formula NI can be prepared by reacting a compound of formula
• the reducing agent may be, for example, hydrogen in the presence of a Group NIII metal catalyst, such as palladium, or a metal hydride reducing agent, such as a borohydride, including sodium triacetoxyborohydride.
• a Group NIII metal catalyst such as palladium
• a metal hydride reducing agent such as a borohydride, including sodium triacetoxyborohydride.
• Convenient solvents include alcohols, such as methanol.
• the reaction is conveniently performed at a temperature in the range of from 0°C to 100°C.
• the compounds of formula NIII may be prepared by oxidizing a compound corresponding to formula III in which Z 1 represents a hydroxyl group.
• Such oxidation reactions can be conducted, for example, using sulfur dioxide pyridine complex in dimethylsulfoxide in the presence of a tertiary amine, such as diisopropylethylamine.
• the reducing agent may be, for example, hydrogen in the presence of a Group NIII metal catalyst, such as palladium, or a metal hydride reducing agent including borohydrides, such as sodium triacetoxyborohydride, optionally used in combination with a titanium tetraalkoxide, such as titanium tetraisopropoxide.
• Convenient solvents include alcohols, such as methanol and halogenated hydrocarbons, such as dichloromethane. The reaction is conveniently performed at a temperature in the range of from 0°C to l00°C.
• Compounds of formula IX can be prepared by oxidizing a compound of formula
• XNII using a suitable oxidizing agent, such as sulfur trioxide pyridine complex in dimethyl sulfoxide in the presence of a tertiary amine base, such as di-isopropylethylamine.
• a suitable oxidizing agent such as sulfur trioxide pyridine complex in dimethyl sulfoxide in the presence of a tertiary amine base, such as di-isopropylethylamine.
• a suitable oxidizing agent such as sulfur trioxide pyridine complex in dimethyl sulfoxide in the presence of a tertiary amine base, such as di-isopropylethylamine.
• a suitable oxidizing agent such as sulfur trioxide pyridine complex in dimethyl sulfoxide in the presence of a tertiary amine base, such as di-isopropylethylamine.
• R 8 represents a (1-6C) alkyl group, such as methyl
• a compound of formula XIX HOOCCH 2 CH 2 (CH 2 ) r - 1 COOR 8 (XIX) in the presence of a coupling agent, such as l-(3-dimethylaminopropyl)-3- ethylcarbodiimide (EDC) or 1-hydroxybenzotriazole hydrate (HOBT).
• a coupling agent such as l-(3-dimethylaminopropyl)-3- ethylcarbodiimide (EDC) or 1-hydroxybenzotriazole hydrate (HOBT).
• EDC l-(3-dimethylaminopropyl)-3- ethylcarbodiimide
• HOBT 1-hydroxybenzotriazole hydrate
• a compound of formula I may be reacted with bromine to afford a corresponding compound of formula I in which R 2 , for example, represents a bromo group.
• a compound of formula I in which R 4 represents a hydrogen atom may be alkylated to afford a corresponding compound of formula I in which R 4 represents a (1-4C) alkyl group.
• compositions and Formulations The biphenyl compounds of this invention are typically administered to a patient in the form of a pharmaceutical composition or formulation.
• Such pharmaceutical compositions may be administered to the patient by any acceptable route of administration including, but not limited to, inhaled, oral, nasal, topical (including transdermal) and parenteral modes of administration ⁇ It will be understood that any form of the compounds of this invention, (i.e., free base, pharmaceutically acceptable salt, solvate, etc.) that is suitable for the particular mode of administration can be used in the pharmaceutical compositions discussed herein.
• this invention is directed to a pharmaceutical composition
• a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• pharmaceutical compositions may contain other therapeutic and/or formulating agents if desired.
• the pharmaceutical compositions of this invention typically contain a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• such pharmaceutical compositions will contain from about 0.01 to about 95% by weight of the active agent; including, from about 0.01 to about 30% by weight; such as from about 0.01 to about 10% by weight of the active agent.
• any conventional carrier or excipient may be used in the pharmaceutical compositions of this invention.
• the choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of medical condition or disease state.
• the preparation of a suitable pharmaceutical composition for a particular mode of administration is well within the scope of those skilled in the pharmaceutical arts.
• the ingredients for such compositions are commercially available from, for example, Sigma, P.O. Box 14508, St. Louis, MO 63178.
• conventional formulation techniques are described in Remington: ⁇ ie Science and Practice of Pharmacy, 20 th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and H.C.
• compositions which can serve as pharmaceutically acceptable carriers include, but are not limited to, the following: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) estradiols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) estradiol, such as
• compositions of this invention are typically prepared by thoroughly and intimately mixing or blending a compound of the invention with a pharmaceutically acceptable carrier and one or more optional ingredients. If necessary or desired, the resulting uniformly blended mixture can then be shaped or loaded into tablets, capsules, pills, canisters, cartridges, dispensers and the like using conventional procedures and equipment.
• the pharmaceutical compositions of this invention are suitable for inhaled administration. Suitable pharmaceutical compositions for inhaled administration will typically be in the form of an aerosol or a powder.
• Such compositions are generally administered using well-known delivery devices, such as a nebulizer inhaler, a metered-dose inhaler (MDI), a dry powder inhaler (DPI) or a similar delivery device.
• the pharmaceutical composition comprising the active agent is administered by inhalation using a nebulizer inhaler.
• a nebulizer inhaler typically produce a stream of high velocity air that causes the pharmaceutical composition comprising the active agent to spray as a mist that is carried into the patient's respiratory tract.
• the active agent when formulated for use in a nebulizer inhaler, is typically dissolved in a suitable carrier to form a solution.
• the active agent can be micronized and combined with a suitable carrier to form a suspension of micronized particles of respirable size, where micronized is typically defined as having about 90% or more of the particles with a diameter of less than about 10 ⁇ m.
• Suitable nebulizer devices are provided commercially, for example, by PAR! GmbH (Starnberg, German).
• Other nebulizer devices include Respimat (Boehringer Ingelheim) and those disclosed, for example, in U.S. Patent No. 6,123,068 to Lloyd et al. and WO
• a representative pharmaceutical composition for use in a nebulizer inhaler comprises an isotonic aqueous solution comprising from about 0.05 ⁇ g/mL to about 10 mg/mL of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• the pharmaceutical composition comprising the active agent is administered by inhalation using a dry powder inhaler.
• Such dry powder inhalers typically administer the active agent as a free-flowing powder that is dispersed in a patient's air-stream during inspiration.
• the active agent is typically formulated with a suitable excipient such as lactose or starch.
• a representative pharmaceutical composition for use in a dry powder inhaler comprises dry lactose having a particle size between about 1 ⁇ m and about 100 ⁇ m and micronized particles of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• a dry powder formulation can be made, for example, by combining the lactose with the active agent and then dry blending the components.
• the active agent can be formulated without an excipient.
• the pharmaceutical composition is then typically loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device.
• dry powder inhaler delivery devices include Diskhaler (GlaxoSmithKline, Research Triangle Park, NC) (see, e.g., U.S. Patent No. 5,035,237 to Newell et al.); Diskus (GlaxoSmithKline) (see, e.g., U.S. Patent No. 6,378,519 to Davies et al.); Turbuhaler (AstraZeneca, Wilmington, DE) (see, e.g., U.S. Patent No. 4,524,769 to Wetterlin); Rotahaler (GlaxoSmithKline) (see, e.g., U.S. Patent No.
• the pharmaceutical composition comprising the active agent is administered by inhalation using a metered- dose inhaler.
• metered-dose inhalers typically discharge a measured amount of the active agent or a pharmaceutically acceptable salt or solvate or stereoisomer thereof using compressed propellant gas.
• compositions administered using a metered-dose inhaler typically comprise a solution or suspension of the active agent in a liquefied propellant.
• a liquefied propellant may be employed including chlorofluorocarbons, such as CC1 3 F, and hydrofluoroalkanes (HFAs), such as 1,1,1,2- tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro-rc- ⁇ ropane, (HFA 227).
• chlorofluorocarbons such as CC1 3 F
• HFAs hydrofluoroalkanes
• HFA 134a 1,1,1,2- tetrafluoroethane
• HFA 227 1,1,1,2,3,3,3-heptafluoro-rc- ⁇ ropane
• HFAs are generally preferred. Additional optional components of HFA formulations include co-solvents, such as ethanol or pentane, and surfactants, such as sorbitan trioleate, oleic acid, lecithin, and glycerin. See, for example, U.S. Patent No. 5,225,183 to Purewal et al., EP 0717987 A2 (Minnesota Mining and Manufacturing Company), and WO
• a representative pharmaceutical composition for use in a metered-dose inhaler comprises from about 0.01 % to about 5 % by weight of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof; from about 0 % to about 20 % by weight ethanol; and from about 0 % to about 5 % by weight surfactant; with the remainder being an HFA propellant.
• Such compositions are typically prepared by adding chilled or pressurized hydrofluoroalkane to a suitable container containing the active agent, ethanol (if present) and the surfactant (if present). To prepare a suspension, the active agent is micronized and then combined with the propellant. The formulation is then loaded into an aerosol canister, which forms a portion of a metered-dose inhaler device. Examples of metered-dose inhaler devices developed specifically for use with HFA propellants are provided in U.S. Patent
• a suspension formulation can be prepared by spray drying a coating of surfactant on micronized particles of the active agent. See, for example, WO 99/53901 (Glaxo Group Ltd.) and WO
• compositions of this invention are suitable for oral administration.
• Suitable pharmaceutical compositions for oral administration maybe in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders, granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each containing a predetermined amount of a compound of the present invention as an active ingredient.
• compositions of this invention When intended for oral administration in a solid dosage fonn (i.e., as capsules, tablets, pills and the like), the pharmaceutical compositions of this invention will typically comprise a compound of the present invention as the active ingredient and one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate.
• pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate.
• such solid dosage forms may also comprise: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and/or glycerol monostearate; (8) absorbents, such as kaolin and/or bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid poly
• antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
• water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like
• oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin
• Coating agents for tablets, capsules, pills and like include those used for enteric coatings, such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PNAP), hydroxypropyl methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like.
• enteric coatings such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PNAP), hydroxypropyl methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like.
• the pharmaceutical compositions of the present invention may also be formulated to provide slow or controlled release of the active ingredient using, by way of example, hydroxypropyl methyl cellulose in varying proportions; or other polymer matrices, liposomes and/or microspheres.
• the pharmaceutical compositions of the present invention may optionally contain opacifying agents and may be formulated so that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
• the active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
• Suitable liquid dosage forms for oral administration include, by way of illustration, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
• Such liquid dosage forms typically comprise the active ingredient and an inert diluent, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
• an inert diluent such as, for example, water or other solvents, solubilizing agents and emulsifier
• Suspensions in addition to the active ingredient, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
• the pharmaceutical compositions of this invention are preferably packaged in a unit dosage form.
• the term "unit dosage form" means a physically discrete unit suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect either alone or in combination with one or more additional units.
• such unit dosage forms may be capsules, tablets, pills, and the like.
• the compounds of this invention can also be administered transdermally using known transdermal delivery systems and excipients.
• a compound of this invention can be admixed with permeation enhancers, such as propylene glycol, polyethylene glycol monolaurate, azacycloalkan-2-ones and the like, and incorporated into a patch or similar delivery system. Additional excipients including gelling agents, emulsifiers and buffers, may be used in such transdermal compositions if desired.
• the pharmaceutical compositions of this invention may also contain other therapeutic agents that are co-administered with a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof.
• the pharmaceutical compositions of this invention may further comprise one or more therapeutic agents selected from other bronchodilators (e.g., PDE 3 inhibitors, adenosine 2b modulators and ⁇ 2 adrenergic receptor agonists); anti-inflammatory agents (e.g., steroidal i anti-inflammatory agents, such as corticosteroids; non-steroidal anti-inflammatory agents (NSAIDs), and PDE 4 inhibitors); other muscarinic receptor antagonists (i.e., antichlolinergic agents); antiinfective agents (e.g., Gram positive and Gram negative antibiotics or antivirals); antihistamines; protease inhibitors; and afferent blockers (e.g., D 2 agonists and neurokinin modulators).
• bronchodilators e.g., PDE 3 inhibitors, adenosine 2b modulators and ⁇ 2 adrenergic receptor agonists
• anti-inflammatory agents e.g., steroidal i
• the compound of the invention is co-administered with a ⁇ 2 adrenergic receptor agonist and a steroidal anti-inflammatory agent.
• the other therapeutic agents can be used in the form of phannaceutically acceptable salts or solvates. Additionally, if appropriate, the other therapeutic agents can be used as optically pure stereoisomers.
• Representative ⁇ 2 adrenergic receptor agonists that can be used in combination with the compounds of this invention include, but are not limited to, salmeterol, salbutamol, formoterol, salmefamol, fenoterol, terbutaline, albuterol, isoetharine, metaproterenol, bitolterol, pirbuterol, levalbuterol and the like, or pharmaceutically acceptable salts thereof.
• ⁇ 2 adrenergic receptor agonists that can be used in combination with the compounds of this invention include, but are not limited to, 3-(4- ⁇ [6-( ⁇ (2R)-2-hydroxy-2-[4-hydroxy- 3-(hydroxymethyl)-phenyl]ethyl ⁇ amino)-hexyl]oxy ⁇ butyl)benzenesulfonamide and 3-(-3- ⁇ [7-( ⁇ (2R)-2-hydroxy-2- [4-hydroxy-3 -(hydroxymethyl)phenyl] ethyl ⁇ -amino)heptyl] oxy ⁇ - propyl)benzenesulfonamide and related compounds disclosed in WO 02/066422 (Glaxo Group Ltd.); 3-[3-(4- ⁇ [6-([(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl ⁇ amino)hexyl]oxy ⁇ butyl)-phenyl]imidazolidine-2,4
• Patent No. 6,576,793 to Mora et al. N- ⁇ 2-[4-(3-phenyl-4- methoxyphenyl)aminophenyl]ethyl ⁇ -(R)-2-hydroxy-2-(8-hydroxy-2(lH)-quinolinon-5- yl)ethylamine and related compounds disclosed in U.S. Patent No. 6,653,323 to Moran et al.; and pharmaceutically acceptable salts thereof.
• the ⁇ - adrenoreceptor agonist is a crystalline monohydrochloride salt of N- ⁇ 2-[4-((R)-2-hydroxy- 2-phenylethylamino)phenyl]ethyl ⁇ -(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine.
• the ⁇ 2 -adrenoreceptor agonist will be present in the pharmaceutical composition in a therapeutically effective amount.
• the ⁇ 2 - adrenoreceptor agonist will be present in an amount sufficient to provide from about 0.05 ⁇ g to about 500 ⁇ g per dose.
• steroidal anti-inflammatory agents that can be used in combination with the compounds of this invention include, but are not limited to, methyl prednisolone, predmsolone, dexamethasone, fluticasone propionate, 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2- furanylcarbonyl)oxy] - 11 ⁇ -hydroxy- 16 ⁇ -methyl-3-oxoandrosta- 1 ,4-diene- 17 ⁇ -carbotl ⁇ ioic acid S-fluoromethyl ester, 6 ⁇ ,9 ⁇ -difluoro-l 1 ⁇ -hydroxy- 16 ⁇ -methyl-3-oxo-17 ⁇ - propionyloxy-androsta- 1 ,4-diene- 17 ⁇ -carbothioic acid S-(2-oxo-tetrahydrofuran-3 S-yl) ester, beclomethasone esters (e.g., the 17-propionate ester or the 17,21-dipro ⁇ ionate ester), budesonide
• the steroidal anti- inflammatory agent When employed, the steroidal anti- inflammatory agent will be present in the pharmaceutical composition in a therapeutically effective amount. Typically, the steroidal anti-inflammatory agent will be present in an amount sufficient to provide from about 0.05 ⁇ g to about 500 ⁇ g per dose.
• An exemplary combination is a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof, co-administered with salmeterol as the ⁇ adrenergic receptor agonist, and fluticasone propionate as the steroidal anti-inflammatory agent.
• Another exemplary combination is a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof, co-administered with a crystalline monohydrochloride salt of N- ⁇ 2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl] ethyl ⁇ -(R)- 2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine as the ⁇ 2 -adrenoreceptor agonist, and 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-l l ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta- l,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester as the steroidal anti-inflammatory agent.
• NSAlDs such as sodium cromoglycate; nedocromil sodium; phosphodiesterase (PDE) inhibitors (e.g., theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors); leukotriene antagonists (e.g., monteleukast); inhibitors of leukotriene synthesis; iNOS inhibitors; protease inhibitors, such as tryptase and elastase inhibitors; beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g., adenosine 2a agonists); cytokine antagonists (e.g., chemokme antagonists such as, an interleukin antibody ( ⁇ lL antibody), specifically, an ⁇ IL-4 therapy, an ⁇ IL-13 therapy, or a combination thereof); or inhibitors of cytokine synthesis.
• NSAlDs such as sodium cromoglycate; nedocromil sodium;
• representative phosphodiesterase-4 (PDE4) inhibitors or mixed PDE3/PDE4 inhibitors that can be used in combination with the compounds of this invention include, but are not limited to cis 4-cyano-4-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexan-l -carboxylic acid, 2-carbomethoxy-4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan- 1 -one; cts-[4-cyano-4-(3 - cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan- 1 -ol] ; cts-4-cyano-4- [3 - (cyclopentyloxy)-4-methoxyphenyl]cyclohexane-l -carboxylic acid and the like, or pharmaceutically acceptable salts thereof.
• PDE4/PDE3 inhibitors include AWD-12-281 (elbion); NCS-613 (INSERM); D-4418 (Chiroscience and Schering-Plough); CI-1018 or PD-168787 (Pfizer); benzodioxole compounds disclosed in WO99/16766 (Kyowa Hakko); K-34 (Kyowa Hakko); V-l 1294A (Napp); roflumilast (Byk-Gulden); pthalazinone compounds disclosed in WO99/47505 (Byk-Gulden); Pumafentrine (Byk-Gulden, now Altana); arofylline (Almirall-
• muscarinic antagonists i.e., anticholinergic agents
• Representative muscarinic antagonists include, but are not limited to, atropine, atropine sulfate, atropine oxide, methylatropine nitrate, homatropine hydrobromide, hyoscyamine (d, I) hydrobromide, scopolamine hydrobromide, ipratropium bromide, oxitropium bromide, tiotropium bromide, methantheline, propantheline bromide, anisotropine methyl bromide, clidinium bromide, copyrrolate (Robinul), isopropamide iodide, mepenzolate bromide, tridihexethyl chloride (P
• antihistamines i.e., H receptor antagonists
• ethanolamines such as carbinoxamine maleate, clemastine fumarate, diphenylhydramine hydrochloride and dimenhydrinate
• ethylenediamines such as pyrilamine amleate, tripelennamine hydrochloride and tripelennamine citrate
• alkylamines such as chlorpheniramine and acrivastine
• piperazines such as hydroxyzine hydrochloride, hydroxyzine pamoate, cyclizine hydrochloride, cyclizine lactate, meclizine hydrochloride and cetirizine hydrochloride
• piperidines such as astemizole, levocabastine hydrochloride, loratadine or its descarboethoxy analogue, terfenadine and fexofenadine hydrochloride
• azelast such as astemizole, levocabastine hydrochloride, lor
• a dry powder for administration by inhalation is prepared as follows: Ingredients Amount Compound of the invention 0.2 mg Lactose 25 mg Representative Procedure: The compound of the invention is micronized and then blended with lactose. This blended mixture is then loaded into a gelatin inhalation cartridge. The contents of the cartridge are administered using a powder inhaler.
• a dry powder formulation for use in a dry powder inhalation device is prepared as follows: Representative Procedure: A pharmaceutical composition is prepared having a bulk formulation ratio of micronized compound of the invention to lactose of 1 :200. The composition is packed into a dry powder inhalation device capable of delivering between about 10 ⁇ g and about lOO ⁇ g of the compound of the invention per dose.
• Formulation Example C A dry powder for administration by inhalation in a metered dose inhaler is prepared as follows: Representative Procedure: A suspension containing 5 wt% of a compound of the invention and 0.1 wt% lecithin is prepared by dispersing 10 g of the compound of the invention as micronized particles with mean size less than 10 ⁇ m in a solution formed from i
• a pharmaceutical composition for use in a metered dose inhaler is prepared as follows: Representative Procedure: A suspension containing 5 wt% compound of the invention, 0.5 wt% lecithin, and 0.5 wt% trehalose is prepared by dispersing 5 g of active ingredient as micronized particles with mean size less than 10 ⁇ m in a colloidal solution formed from 0.5 g of trehalose and 0.5 g of lecithin dissolved in 100 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 ⁇ m. The particles are loaded into canisters with pressurized 1,1,1,2-tetrafluoroethane.
• a pharmaceutical composition for use in a nebulizer inhaler is prepared as follows: Representative Procedure: An aqueous aerosol formulation for use in a nebulizer is prepared by dissolving 0.1 mg of the compound of the invention in 1 mL of a 0.9 % sodium chloride solution acidified with citric acid. The mixture is stirred and sonicated until the active ingredient is dissolved. The pH of the solution is adjusted to a value in the range of from 3 to 8 by the slow addition of NaOH.
• Hard gelatin capsules for oral administration are prepared as follows: Ingredients Amount Compound of the invention 250 mg Lactose (spray-dried) 200 mg Magnesium stearate 10 mg Representative Procedure: The ingredients are thoroughly blended and then loaded into a hard gelatin capsule (460 mg of composition per capsule).
• a suspension for oral administration is prepared as follows: Ingredients Amount Compound of the invention 1.0 g Fumaric acid 0.5 g Sodium chloride 2.0 g Methyl paraben 0.15 g Propyl paraben 0.05 g Granulated sugar 25.5 g Sorbitol (70% solution) 12.85 g Veegum k (Vanderbilt Co.) 1.0 g Flavoring 0.035 mL Colorings 0.5 mg Distilled water q.s. to 100 mL
• Formulation Example H An injectable formulation is prepared as follows: Ingredients Amount Compound of the invention 0.2 g Sodium acetate buffer solution (0.4 M) 2.0 mL HCl (0.5 N) or NaOH (0.5 N) q.s. to pH 4 Water (distilled, sterile) q.s. to 20 mL
• the above ingredients are blended and the pH is adjusted to 4 ⁇ 0.5 using 0.5 N HCl or 0.5 N NaOH.
• the biphenyl compounds of this invention are expected to be useful as muscarinic receptor antagonists and therefore, such compounds are expected to be useful for treating medical conditions mediated by muscarinic receptors, i.e., medical conditions which are ameliorated by treatment with a muscarinic receptor antagonist.
• Such medical conditions include, by way of example, pulmonary disorders or diseases including those associated with reversible airway obstruction, such as chronic obstructive pulmonary disease (e.g., chronic and whez bronchitis and emphysema), asthma, pulmonary fibrosis, allergic rhinitis, rhinorrhea, and the like.
• chronic obstructive pulmonary disease e.g., chronic and whez bronchitis and emphysema
• asthma pulmonary fibrosis
• allergic rhinitis rhinitis
• rhinorrhea and the like.
• muscarinic receptor antagonists include genitourinary tract disorders, such as overactive bladder or detrusor hyperactivity and their symptoms; gastrointestinal tract disorders, such as irritable bowel syndrome, diverticular disease, achalasia, gastrointestinal hypermotility disorders and diarrhea; cardiac arrhythmias, such as sinus bradycardia; Parkinson's disease; cognitive disorders, such as Alzheimer's disease; dismenorrhea; and the like.
• the compounds of this invention are useful for treating smooth muscle disorders in mammals, including humans and their companion animals (e.g., dogs, cats etc.).
• smooth muscle disorders include, by way of illustration, overactive bladder, chronic obstructive pulmonary disease and irritable bowel syndrome.
• the compounds of this invention When used to treat smooth muscle disorders or other conditions mediated by muscarinic receptors, the compounds of this invention will typically be administered orally, rectally, parenterally or by inhalation in a single daily dose or in multiple doses per day.
• the amount of active agent administered per dose or the total amount administered per day will typically be determined by the patient's physician and will depend on such factors as the nature and severity of the patients condition, the condition being treated, the age and general health of the patient, the tolerance of the patient to the active agent, the route of administration and the like.
• suitable doses for treating smooth muscle disorders or other disorders mediated by muscarinic receptors will range from about 0.14 ⁇ g/kg/day to about 7 mg/kg/day of active agent; including from about 0.15 ⁇ g/kg/day to about 5 mg/kg/day. For an average 70 kg human, this would amount to about 10 ⁇ g per day to about 500 mg per day of active agent.
• the compounds of this invention are useful for treating pulmonary or respiratory disorders, such as COPD or asthma, in mammals including humans. When used to treat such disorders, the compounds of this invention will typically be administered by inhalation in multiple doses per day, in a single daily dose or a single weekly dose.
• the dose for treating a pulmonary disorder will range from about 10 ⁇ g/day to about 200 ⁇ g/day.
• COPD includes chronic obstructive bronchitis and emphysema (see, for example, Barnes, Chronic Obstructive Pulmonary Disease, N EnglJ Med 343:269-78 (2000)).
• the compounds of this invention are optionally administered in combination with other therapeutic agents such as a ⁇ 2 - adrenoreceptor agonist; a corticosteroid, a non-steroidal anti-inflammatory agent, or combinations thereof.
• the compounds of this invention typically have the effect of producing bronchodilation.
• this invention is directed to a method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of the invention.
• the therapeutically effective dose for producing bronchodilation will range from about 10 ⁇ g/day to about 200 ⁇ g/day :
• the compounds of this invention are used to treat overactive bladder.
• the compounds of this invention When used to treat overactive bladder, the compounds of this invention will typically be administered orally in a single daily dose or in multiple doses per day; preferably in a single daily dose.
• the dose for treating overactive bladder will range from about 1.0 to about 500 mg/day.
• the compounds of this invention are used to treat irritable bowel syndrome.
• the compounds of this invention When used to treat irritable bowel syndrome, the compounds of this invention will typically be administered orally or rectally in a single daily dose or in multiple doses per day. Preferably, the dose for treating irritable bowel syndrome will range from about 1.0 to about 500 mg/day.
• compounds of this invention are muscarinic receptor antagonists, such compounds are also useful as research tools for investigating or studying biological systems or samples having muscarinic receptors. Such biological systems or samples may comprise M ls M 2 , M 3 , 4 and/or M 5 muscarinic receptors.
• Any suitable biological system or sample having muscarinic receptors may be employed in such studies which may be conducted either in vitro or in vivo.
• Representative biological systems or samples suitable for such studies include, but are not limited to, cells, cellular extracts, plasma membranes, tissue samples, mammals (such as mice, rats, guinea pigs, rabbits, dogs, pigs, etc.), and the like.
• a biological system or sample comprising a muscarinic receptor is contacted with a muscarinic receptor-antagonizing amount of a compound of this invention.
• the effects of antagonizing the muscarinic receptor are then determined using conventional procedures and equipment, such as radioligand binding assays and functional assays.
• Such functional assays include ligand-mediated changes in intracellular cyclic adenosine monophosphate (cAMP), ligand-mediated changes in activity of the enzyme adenylyl cyclase (which synthesizes cAMP), ligand-mediated changes in incorporation of guanosine 5 ' -O-( ⁇ -thio)triphosphate ([ 35 S] GTP ⁇ S) into isolated membranes via receptor catalyzed exchange of [ 35 S]GTP ⁇ S for GDP, ligand-mediated changes in free intracellular calcium ions (measured, for example, with a fluorescence- linked imaging plate reader or FLIPR ® from Molecular Devices, Inc.).
• cAMP cyclic adenosine monophosphate
• adenylyl cyclase which synthesizes cAMP
• ligand-mediated changes in incorporation of guanosine 5 ' -O-( ⁇ -thio)triphosphate [ 35 S] GTP ⁇ S
• a compound of this invention will antagonize or decrease the activation of muscarinic receptors in any of the functional assays listed above, or assays of a similar nature.
• a muscarinic receptor- antagonizing amount of a compound of this invention will typically range from about 0.1 nanomolar to about 100 nanomolar. Additionally, the compounds of this invention can be used as research tools for discovering new compounds that have muscarinic receptor antagonist activity.
• muscarinic receptor binding data (e.g., as determined by in vitro radioligand displacement assays) for a test compound or a group of test compounds is compared to the muscarinic receptor binding data for a compound of this invention to identify those test compounds that have about equal or superior muscarinic receptor binding, if any.
• This aspect of the invention includes, as separate embodiments, both the generation of comparison data (using the appropriate assays) and the analysis of the test data to identify test compounds of interest.
• the compounds of this invention are used to antagonize a muscarinic receptor in biological system, and a mammal in particular, such as mice, rats, guinea pigs, rabbits, dogs, pigs, humans and so forth.
• a therapeutically effective amount of the compound of formula I is administered to the mammal.
• the effects of antagonizing the muscarinic receptor can then determined using conventional procedures and equipment, examples of which are described above.
• compounds of this invention have been found to be potent inhibitors of M 3 muscarinic receptor activity. Accordingly, in a specific embodiment, this invention is directed to compounds of formula I having an inhibition dissociation constant (Kj) for the M 3 receptor subtype of less than or equal to 10 nM; preferably, less than or equal to 5 nM; (as determined, for example, by an in vitro radioligand displacement assay). Additionally, compounds of this invention are expected to possess a desirable duration of action.
• Kj inhibition dissociation constant
• this invention is directed to compounds of formula I having a duration of action greater than or equal to about 24 hours.
• compounds of this invention are also expected to possess reduced side effects, such as dry mouth, at efficacious doses when administered by inhalation compared to other known muscarinic receptor antagonists administered by inhalation (such as tiotropium).
• HPLC 10-70 data was obtained using a flow rate of 0.5 mL/minute of 10 to 70% B over a 6 minute gradient (with the remainder being A).
• HPLC 5-35 data and HPLC 10-90 data were obtained using 5 to 35% B; or 10 to 90% B over a 5 minute gradient.
• Liquid chromatography mass spectrometry (LCMS) data were obtained with an Applied Biosystems (Foster City, CA) Model API-150EX instrument.
• LCMS 10-90 data was obtained using 10 to 90% Mobile Phase B over a 5 minute gradient.
• Small-scale purification was conducted using an API 150EX Prep Workstation system from Applied Biosystems.
• the mobile phases employed were as follows (by volume): A is water and 0.05% TFA; and B is ACN and 0.05% TFA.
• A is water and 0.05% TFA
• B is ACN and 0.05% TFA.
• For arrays typically about 3 to 50 mg recovered sample size the following conditions were used: 20 mL/min flow rate; 15 min gradients and a 20 mm x 50 mm Prism RP column with 5 micron particles (Thermo Hypersil-Keystone, Bellefonte, PA).
• Biphenyl-2-ylcarbamic Acid Piperidin-4-yl Ester Biphenyl-2-isocyanate (97.5 g, 521 mmol) and 4-hydroxy-N-benzylpiperidine (105 g, 549 mmol) were heated together at 70°C for 12 hours. The reaction mixture was then cooled to 50°C and EtOH (1 L) was added and then 6M HCl (191 mL) was added slowly. The resulting mixture was then cooled to ambient temperature and ammonium formate (98.5 g, 1.56 mol) was added and then nitrogen gas was bubbled through the solution vigorously for 20 minutes.
• N-Benzyl-N-methylaminoacetaldehyde To a 3-necked 2-L flask was added N-benzyl-N-methylethanolamine (30.5 g, 0.182 mol), DCM (0.5 L), DIPEA (95 mL, 0.546 mol) and DMSO (41 mL, 0.728 mol). Using an ice bath, the mixture was cooled to about -10°C and sulfur trioxide pyridine- complex (87 g, 0.546 mol) was added in 4 portions over 5 minutes intervals. The reaction was stirred at — 10°C for 2 hours. Before removing the ice-bath, the reaction was quenched by adding water (0.5 L).
• Example 4 Biphenyl-2-ylcarbamic acid l-(2- ⁇ [6-((R)-3-ethylcarbamoylpiperidin- l-yl)hexanoyl]methylamino ⁇ -ethyl)piperidin-4-yl ester. MS m/z: [M + H + ] calcd for C 35 H 51 N 5 O 4 , 606.40; found, 606.4.
• Example 5 Biphenyl-2-ylcarbamic acid l-(2- ⁇ methyl-[6-((R)-3-propylcarbamoyl piperidin-l-yl)hexanoyl]amino ⁇ ethyl)piperidin-4-yl ester.
• Example 9 Biphenyl-2-ylcarbamic acid l- ⁇ 2-[6-(4-carbamoylpiperidin-l-yl) hexanoylamino]ethyl ⁇ piperidin-4-yl ester;
• Example 10 Biphenyl-2-ylcarbamic acid l-(2- ⁇ methyl-[6-(4-methylcarbamoyl piperidin- 1 -yl)hexanoyl] amino ⁇ ethyl)piperidin-4-yl ester;
• Example 11 Biphenyl-2-ylcarbamic acid 1 -(2- ⁇ [6-(4-ethylcarbamoylpiperidin- 1 - yl)hexanoyl]methylamino ⁇ ethyl)piperidin-4-yl ester;
• Example 12 Biphenyl-2-ylcarbamic acid
• Assay 1 Radioligand Binding Assay A. Membrane Preparation from Cells Expressing bJVL_, hM 7 , hM 3 and hM Muscarinic Receptor Subtypes CHO cell lines stably expressing cloned human M ⁇ , hM 2 , hM 3 and hM muscarinic receptor subtypes, respectively, were grown to near confluency in medium consisting of HAM's F-12 supplemented with 10% FBS and 250 ⁇ g/mL Geneticin. The cells were grown in a 5% CO 2 , 37°C incubator and lifted with 2 mM EDTA in dPBS.
• Cells were collected by 5 minute centrifugation at 650 x g, and cell pellets were either stored frozen at -80°C or membranes were prepared immediately.
• cell pellets were resuspended in lysis buffer and homogenized with a Polytron PT-2100 tissue disrupter (Kinematica AG; 20 seconds x 2 bursts). Crude membranes were centrifuged at 40,000 x g for 15 minutes at 4°C. The membrane pellet was then resuspended with resuspension buffer and homogenized again with the Polytron tissue disrupter.
• the protein concentration of the membrane suspension was determined by the method described in Lowry, O. et al., Journal of Biochemistry 193:265 (1951).
• CHO cell membranes stably expressing either the nM ls hM 2 , hM 3 , hM 4 or hM 5 muscarinic subtype were diluted in assay buffer to the following specific target protein concentrations ( ⁇ g/well): 10 ⁇ g for hM l5 10-15 ⁇ g for hM 2 , 10-20 ⁇ g for hM 3 , 10-20 ⁇ g for hM 4 , and 10-12 ⁇ g for I1M 5 .
• the membranes were briefly homogenized using a Polytron tissue disruptor (10 seconds) prior to assay plate addition.
• the addition order and volumes to the assay plates were as follows: 25 ⁇ L radioligand, 25 ⁇ L diluted test compound, and 50 ⁇ L membranes. Assay plates were incubated for 60 minutes at 37°C. Binding reactions were terminated by rapid filtration over GF/B glass fiber filter plates (PerkinElmer Inc., Wellesley, MA) pre-treated in 1% BSA. Filter plates were rinsed three times with wash buffer (10 mM HEPES) to remove unbound radioactivity. Plates were then air dried, and 50 ⁇ L Microscint-20 liquid scintillation fluid (PerkinElmer Inc., Wellesley, MA) was added to each well.
• a lower K ; - value indicates that the test compound has a higher binding affinity for the receptor tested.
• the compound of Example 1 was found to have a K ; - value of less than about 5 nM for the M 3 muscarinic receptor subtype in this assay.
• Assay 2 Muscarinic Receptor Functional Potency Assays A. Blockade of Agonist-Mediated Inhibition of cAMP Accumulation
• the functional potency of a test compound is determined by measuring the ability of the test compound to block oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-K1 cells expressing the hM 2 receptor.
• cAMP assays are performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with 125 I-cAMP (NEN SMP004B, PerkinElmer Life Sciences Inc., Boston, MA), according to the manufacturer's instructions.
• Cells are rinsed once with dPBS and lifted with Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA) as described in the Cell Culture and Membrane Preparation section above.
• the detached cells are washed twice by centrifugation at 650 x g for five minutes in 50mLs dPBS.
• the cell pellet is then re-suspended in 10 mL dPBS, and the cells are counted with a Coulter Zl Dual Particle Counter (Beckman Coulter, Fullerton, CA).
• the cells are centrifuged again at 650 x g for five minutes and re-suspended in stimulation buffer to an assay concentration of 1.6 x 10 6 - 2.8 x 10 6 cells/mL.
• the test compound is initially dissolved to a concentration of 400 ⁇ M in dilution buffer (dPBS supplemented with 1 mg/mL BSA (0.1%)), and then serially diluted with dilution buffer to final molar concentrations ranging from 100 ⁇ M to 0.1 nM.
• Oxotremorine is diluted in a similar manner.
• 25 ⁇ L forskolin 25 ⁇ M final concentration diluted in dPBS
• 25 ⁇ L diluted oxotremorine, and 50 ⁇ L cells are added to agonist assay wells.
• 25 ⁇ L forskolin and oxotremorine 25 ⁇ M and 5 ⁇ M final concentrations, respectively, diluted in dPBS
• 25 ⁇ L diluted test compound 25 ⁇ L diluted test compound, and 50 ⁇ L cells are added to remaining assay wells.
• the Cheng-Prusoff equation is used to calculate the K, using the EC 50 of the oxotremorine concentration- response curve and the oxotremorine assay concentration as the Kp and [L], respectively.
• the Kj values are converted to pK values to determine the geometric mean and 95% confidence intervals. These summary statistics are then converted back to K; values for data reporting. In this assay, a lower K; value indicates that the test compound has a higher functional activity at the receptor tested.
• Compounds of this invention are expected to have a K; value of less than about 10 nM for blockade of oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-K1 cells expressing the hM 2 receptor.
• the functional potency of test compounds can be determined by measuring the ability of the compounds to block oxotremorine-stimulated [ 35 S]GTP ⁇ S binding in CHO-K1 cells expressing the hM 2 receptor.
• frozen membranes are thawed and then diluted in assay buffer with a final target tissue concentration of 5-10 ⁇ g protein per well.
• the membranes are briefly homogenized using a Polytron PT-2100 tissue disrupter and then added to the assay plates.
• the EC 90 value (effective concentration for 90% maximal response) for stimulation of [ 35 S]GTP ⁇ S binding by the agonist oxotremorine is determined in each experiment.
• a test compound to inhibit oxotremorine-stimulated [ 35 SJGTP ⁇ S binding, the following is added to each well of 96 well plates: 25 ⁇ L of assay buffer with [ 35 S]GTP ⁇ S (0.4nM), 25 ⁇ L of oxotremorine(EC 90 ) and GDP (3 ⁇ M), 25 ⁇ L of diluted test compound and 25 ⁇ L CHO cell membranes expressing the hM 2 receptor.
• the assay plates are then incubated at 37 °C for 60 minutes.
• the assay plates are filtered over 1% BSA-pretreated GF/B filters using a PerkinElmer 96-well harvester. The plates are rinsed with ice-cold wash buffer for 3 x 3 seconds and then air or vacuum dried.
• Microscint-20 scintillation liquid (50 ⁇ L) is added to each well, and each plate is sealed and radioactivity counted on a topcounter (PerkinElmer). Data are analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, CA) using the non-linear regression, one-site competition equation. The Cheng-Prusoff equation is used to calculate the Ki, using the IC 50 values of the concentration-response curve for the test compound and the oxotremorine concentration in the assay as the K D and [L], ligand concentration, respectively. In this assay, a lower K; value indicates that the test compound has a higher functional activity at the receptor tested.
• Compounds of this invention are expected to have a K; value of less than about 10 nM for blockade of oxotremorine-stimulated [ 35 S]GTP ⁇ S_binding in CHO-K1 cells expressing the hM 2 receptor.
• PLC phospholipase C
• activated PLC hydrolyzes phosphatyl inositol diphosphate (P1P 2 ) to diacylglycerol (DAG) and phosphatidyl-l,4,5-triphosphate (IP 3 ), which in rum generates calcium release from intracellular stores, i.e., endoplasmic and sarcoplasmic reticulum.
• the FLIPR Molecular Devices, Sunnyvale, CA
• assay capitalizes on this increase in intracellular calcium by using a calcium sensitive dye (Fluo-4AM, Molecular Probes, Eugene, OR) that fluoresces when free calcium binds.
• This fluorescence event is measured in real time by the FLIPR, which detects the change in fluorescence from a monolayer of cells cloned with human Mi and M 3 , and chimpanzee M 5 receptors.
• Antagonist potency can be determined by the ability of antagonists to inhibit agonist-mediated increases in intracellular calcium.
• FLIPR calcium stimulation assays CHO cells stably expressing the hMi, hM 3 and cM 5 receptors are seeded into 96-well FLIPR plates the night before the assay is done.
• Seeded cells are washed twice by Cellwash (MTX Labsystems, Inc.) with FLIPR buffer (10 mM HEPES, pH 7.4, 2 mM calcium chloride, 2.5 mM probenecid in Hank's Buffered Salt Solution (HBSS) without calcium and magnesium) to remove growth media and leaving 50 ⁇ L/well of FLIPR buffer.
• FLIPR buffer 10 mM HEPES, pH 7.4, 2 mM calcium chloride, 2.5 mM probenecid in Hank's Buffered Salt Solution (HBSS) without calcium and magnesium
• HBSS Hank's Buffered Salt Solution
• FLUO-4AM a 2X solution was made
• the dose-dependent stimulation of intracellular Ca 2+ release for oxotremorine is first determined so that antagonist potency can later be measured against oxotremorine stimulation at an EC 90 concentration.
• Cells are first incubated with compound dilution buffer for 20 minutes, followed by agonist addition, which is performed by the FLIPR.
• An oxotremorine concentration of 3 x EC F is prepared in stimulation plates such that an EC 90 concentration of oxotremorine is added to each well in the antagonist inhibition assay plates.
• the parameters used for the FLIPR are: exposure length of 0.4 seconds, laser strength of 0.5 watts, excitation wavelength of 488 nm, and emission wavelength of 550 nm. Baseline is determined by measuring the change in fluorescence for 10 seconds prior to addition of agonist. Following agonist stimulation, the FLIPR continuously measured the change of fluorescence every 0.5 to 1 second for 1.5 minutes to capture the maximum fluorescence change. The change of fluorescence is expressed as maximum fluorescence minus baseline fluorescence for each well.
• the raw data is analyzed against the logarithm of drug concentration by nonlinear regression with GraphPad Prism (GraphPad Software, Inc., San Diego, CA) using the built-in model for sigmoidal dose-response.
• Antagonist K values are determined by Prism using the oxotremorine EC 50 value as the K and the oxotremorine
• Kj value indicates that the test compound has a higher functional activity at the receptor tested.
• Compounds of this invention are expected to have a Kj value of less than about 10 nM for blockade of agonist-mediated calcium release in CHO cells stably expressing the hM 3 receptor.
• Assay 3 Determination of Duration of Bronchoprotection in Guinea Pig Model of Acetylcholine-Induced Bronchoconstriction This in vivo assay is used to assess the bronchoprotective effects of test compounds exhibiting muscarinic receptor antagonist activity.
• Groups of six male guinea pigs (Duncan-Hartley (HsdPoc:DH) Harlan, Madison, WI) weighing between 250 and 350 g are individually identified by cage cards. Throughout the study animals are allowed access to food and water ad libitum. Test compounds are administered via inhalation over 10 minutes in a whole-body exposure dosing chamber (R&S Molds, San Carlos, CA). The dosing chambers are arranged so that an aerosol was simultaneously delivered to 6 individual chambers from a central manifold. Guinea pigs are exposed to an aerosol of a test compound or vehicle (WFI). These aerosols are generated from aqueous solutions using an LC Star Nebulizer Set (Model 22F51, PAR!
• the gas flow through the nebulizer at this operating pressure is approximately 3 L/minute.
• the generated aerosols are driven into the chambers by positive pressure. No dilution air is used during the delivery of aerosolized solutions.
• approximately 1.8 mL of solution is nebulized. This is measured gravimetrically by comparing pre-and post-nebulization weights of the filled nebulizer.
• bronchoprotective effects of test compounds administered via inhalation are evaluated using whole body plethysmography at 1.5, 24, 48 and 72 hours post-dose. Forty-five minutes prior to the start of the pulmonary evaluation, each guinea pig is anesthetized with an intramuscular injection of ketamine (43.75 mg/kg), xylazine (3.50 mg/kg) and acepromazine (1.05 mg/kg). After the surgical site is shaved and cleaned with 70% alcohol, a 2-3 cm midline incision of the ventral aspect of the neck was made.
• the jugular vein is isolated and cannulated with a saline-filled polyethylene catheter (PE-50, Becton Dickinson, Sparks, MD) to allow for intravenous infusions of ACh (Sigma- Aldrich, St. Louis, MO) in saline.
• PE-50 Becton Dickinson, Sparks, MD
• ACh Sigma- Aldrich, St. Louis, MO
• the trachea is then dissected free and cannulated with a 14G teflon tube (#NE- 014, Small Parts, Miami Lakes, FL).
• anesthesia is maintained by additional intramuscular injections of the aforementioned anesthetic mixture. The depth of anesthesia is monitored and adjusted if the animal responds to pinching of its paw or if the respiration rate is greater than 100 breaths/minute. Once the cannulations are complete, the animal is placed into a plethysmograph
• a heating lamp is used to maintain body temperature and the guinea pig's lungs are inflated 3 times with 4 mL of air using a 10 mL calibration syringe (#5520 Series, Hans Rudolph, Kansas City, MO) to ensure that the lower airways do not collapse and that the animal does not suffer from hyperventilation.
• the changes in volume over time that occur within the plethysmograph with each breath are measured via a Buxco pressure transducer. By integrating this signal over time, a measurement of flow is calculated for each breath.
• This signal, together with the pulmonary driving pressure changes, which are collected using a Sensym pressure transducer (#TRD4100), is connected via a Buxco (MAX 2270) preamplifier to a data collection interface (#'s SFT3400 and SFT3813). All other pulmonary parameters are derived from these two inputs. Baseline values are collected for 5 minutes, after which time the guinea pigs are challenged with ACh.
• ACh (0.1 mg/mL) is infused intravenously for 1 minute from a syringe pump (sp210iw, World Precision Instruments, Inc., Sarasota, FL) at the following doses and prescribed times from the start of the experiment: 1.9 ⁇ g/minute at 5 minutes, 3.8 ⁇ g/minute at 10 minutes, 7.5 ⁇ g/minute at 15 minutes, 15.0 ⁇ g/minute at 20 minutes, 30 ⁇ g/minute at 25 minutes and 60 ⁇ g/minute at 30 minutes. If resistance or compliance has not returned to baseline values at 3 minutes following each ACh dose, the guinea pig's lungs are inflated 3 times with 4 mL of air from a 10 mL calibration syringe.
• pulmonary parameters includes respiration frequency (breaths/minute), compliance (mL/cm H 2 O) and pulmonary resistance (cm H 2 O/ mL per second).
• respiration frequency breaths/minute
• compliance mL/cm H 2 O
• pulmonary resistance cm H 2 O/ mL per second.
• the mean ACh response in vehicle-treated animals, at each pre-treatment time, is calculated and used to compute % inhibition of ACh response, at the corresponding pre-treatment time, at each test compound dose.
• Inhibition dose-response curves for 'R L ' are fitted with a four parameter logistic equation using GraphPad Prism, version 3.00 for Windows (GraphPad Software, San Diego, California) to estimate bronchoprotective ID 50 (dose required to inhibit the ACh (60 ⁇ g/min) bronchoconstrictor response by 50%).
• Y Min + (Max-Min)/(1 + 10 ((log lO50 ⁇ X)* Hillslope) )
• X is the logarithm of dose
• Y is the response (% Inhibition of ACh induced increase in R L ).
• Y starts at Min and approaches asymptotically to Max with a sigmoidal shape.
• PD 2 which is defined as the amount of ACh or histamine needed to cause a doubling of the baseline pulmonary resistance, is calculated using the pulmonary resistance values derived from the flow and the pressure over a range of ACh or histamine challenges using the following equation (which is derived from a equation used to calculate PC 20 values described in American Thoracic Society.
• An efficacious dose is defined as a dose that limits the bronchrestriction response to a 50 ⁇ g/mL dose of ACh to a doubling of the baseline pulmonary resistance (PD 2(5 o ) ).
• Statistical analysis of the data is performed using a two-tailed Students t-test.
• test compounds having a PD 2 ( 50 ) less than about 200 ⁇ g/mL for ACh- induced bronchoconstriction at 1.5 hours post-dose in this assay are preferred.
• Compounds of the invention are expected to have a PD 2 ( 50 ) of less than about 200 ⁇ g/mL for ACh- induced bronchoconstriction at 1.5 hours post-dose.
• Assay 4 Inhalation Guinea Pig Salivation Assay Guinea pigs (Charles River, Wilmington, MA) weighing 200-350 g are acclimated to the in-house guinea pig colony for at least 3 days following arrival.
• Test compound or vehicle are dosed via inhalation (IH) over a 10 minute time period in a pie shaped dosing chamber (R&S Molds, San Carlos, CA).
• Test solutions are dissolved in sterile water and delivered using a nebulizer filled with 5.0 mL of dosing solution.
• Guinea pigs are restrained in the inhalation chamber for 30 minutes. During this time, guinea pigs are restricted to an area of approximately 110 sq. cm. This space is adequate for the animals to turn freely, reposition themselves, and allow for grooming. Following 20 minutes of acclimation, guinea pigs are exposed to an aerosol generated from a LS Star Nebulizer Set
• Guinea pigs are evaluated at 1.5, 6, 12, 24, 48, or 72 hrs after treatment. Guinea pigs are anesthetized one hour before testing with an intramuscular (IM) injection of a mixture of ketamine 43.75 mg/kg, xylazine 3.5 mg/kg, and acepromazine
• Y Min + (Max-Min)/(1 + 10 ((log ID50 ⁇ X)* Hillslope) )
• X the logarithm of dose
• Y the response (% inhibition of salivation).
• Y starts at Min and approaches asymptotically to Max with a sigmoidal shape.
• the ratio of the anti-sialagogue ID 50 to bronchoprotective ID 5 0 was used to compute the apparent lung-selectivity index of the test compound.
• compounds having an apparent lung-selectivity index greater than about 5 are preferred.
• compounds of the invention are expected to have an apparent lung-selectivity index greater than 5.
• Each animal is administered saline (3 mL, SC) at the end of surgery as well as bupreno hine (0.05 mg/kg, IM). Animals are allowed to recover on a heating pad before being returned to their holding rooms. Approximately 18 to 20 hours following surgery, the animals are weighed and the carotid artery catheter on each animal is connected to a transducer for recording arterial pressure. Arterial pressure and heart rate are recorded using a Biopac MP-100 Acquisition System. Animals are allowed to acclimate and stabilize for a period of 20 minutes. Each animal is challenged with MCh (0.3 mg/kg, IN) administered through theugular venous line and the cardiovascular response is monitored for 10 minutes.
• MCh 0.3 mg/kg, IN
• the animals are then placed into the whole body dosing chamber, which is connected to a nebulizer containing the test compound or vehicle solution.
• the solution is nebulized for 10 minutes using a gas mixture of breathable air and 5% carbon dioxide with a flow rate of 3 liters/minute.
• the animals are then removed from the whole body chamber and returned to their respective cages.
• the animals are re-challenged with MCh (0.3 mg/kg, IN) and the hemodynamic response is determined. Thereafter, the animals are euthanized with sodium pentobarbital (150 mg/kg, JV).
• MCh produces a decrease in mean arterial pressure (MAP) and decrease in heart rate (bradycardia).
• the peak decrease, from baseline, in MAP (depressor responses) is measured for each MCh challenge (before and after IB dosing).
• the effects of treatment on the MCh responses are expressed as % inhibition (mean +/- SEM) of the control depressor responses.
• Two-way A ⁇ OVA with the appropriate post-hoc test is used to test the effects of treatment and pre-treatment time.
• the depressor responses to MCh are expected to be relatively unchanged at 1.5 and 24 h after inhalation dosing with vehicle.
• the ratio of the anti-depressor ID 5 o to bronchoprotective ID 50 is used to compute apparent lung-selectivity of the test compound. Generally, compounds having an apparent lung-selectivity index greater than 5 are preferred.

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34962793

Family Applications (1)

Country Status (4)

Cited By (2)

Families Citing this family (15)

Citations (4)

Family Cites Families (24)

• 2005
  • 2005-03-10 EP EP05725247A patent/EP1723112A1/en not_active Withdrawn
  • 2005-03-10 WO PCT/US2005/007956 patent/WO2005087736A1/en not_active Application Discontinuation
  • 2005-03-10 JP JP2007503003A patent/JP2007528408A/ja not_active Withdrawn
  • 2005-03-10 US US11/077,345 patent/US7262205B2/en active Active
• 2007
  • 2007-07-19 US US11/879,829 patent/US7851631B2/en not_active Expired - Fee Related
• 2010
  • 2010-11-03 US US12/938,539 patent/US8067439B2/en not_active Expired - Fee Related

Patent Citations (4)

Also Published As

Similar Documents

Legal Events